Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
OtoJig is a minimally invasive otologic surgery system developed by Germany’s OtoJig GmbH, with a primary focus on cochlear implantation. Its official website states that the goal is to turn what is traditionally a more invasive cochlear implant procedure into a safer, faster, and more affordable minimally invasive intervention. It is not a standard hearing aid or consumer medical product, but a high-precision medical device platform designed for hospitals and surgeons.
The system consists of the conCIerge imaging and planning software plus various hardware components. Surgeons first perform 3D trajectory planning based on CT scans, then use the Mini-Stereotactic Frame, X-Ray Marker, and a patient-specific Positioning Jig to constrain the drill along the preplanned path. The positioning jig can be automatically manufactured on the hospital side, with the website claiming that customized production takes only a few minutes. The aim is to access the inner ear region through a single small drill channel, reducing bone removal and lowering reliance on a surgeon’s manual experience or large navigation/robotic systems.
The official website does not disclose pricing, subscription fees, equipment purchase costs, or consumable expenses. Given that the system includes planning software, in-hospital manufacturing equipment, surgical frames, and disposable/specialized instruments, its actual business model is likely a combination of hospital equipment procurement, software licensing, and consumables. However, its roadmap currently indicates that German CE marking and market launch are expected in 2027, suggesting that it has not yet been fully commercialized.
Its strength lies in a highly focused technical approach: using patient-specific jigs to improve the accuracy and standardization of cochlear implantation, while potentially shortening surgery and anesthesia time. It is also backed by research projects, patents, first-in-human studies, and MED-EL as a strategic investor. The limitations are also clear: clinical evidence and regulatory certification are still in progress, and the website lacks large-scale efficacy data, failure rates, training system details, and commercial after-sales information. Some instruments are also specifically adapted for MED-EL FLEX electrodes, so ecosystem compatibility still needs to be verified.
OtoJig is suitable for ENT cochlear implant centers, hospitals performing temporal bone microsurgery, medical device clinical research teams, and surgical teams looking to reduce the invasiveness and technical barriers of cochlear implantation. It is not intended for ordinary patients to purchase directly. Patients should instead consult hospitals and physicians to learn whether they may be eligible for related clinical studies or future use.
The website itself is directly accessible and its content is in English. The company has mentioned that related patents have been granted in China, but there is no visible information on Chinese registration certificates, distribution channels, or local clinical implementation. For hospitals in China, actual adoption will still depend on NMPA registration, clinical access, training, and after-sales support.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on otojig.com official site.
otojig.com is an Switzerland Health provider. TG4G tracks its product information, an overall rating of 7.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach otojig.com directly.